Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 722173 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
| More
Site LicenseAdd to Basket
EnterprisewideAdd to Basket
EnterprisewideAdd to Basket
Site LicenseAdd to Basket

<< Back to Search Results



European Autoimmune Diseases Therapeutics Markets
Frost & Sullivan, Jan 2007


  Description  
  Table of Contents  
    
    
    
   
 Enquire before Buying  
 Send to a Friend  

This Frost & Sullivan research service titled European Autoimmune Disease Therapeutics Market provides an overview of current treatment options, drugs in pipeline and technological advancements in the market. It also a complete analysis of key market drivers, restraints and revenues involved in the current rheumatoid arthritis and multiple sclerosis medications. In this research, Frost & Sullivan's expert analysts thoroughly examine the following therapeutics markets for rheumatoid arthritis and multiple sclerosis.

Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:

-Rheumatoid arthritis therapeutics
-Multiple sclerosis therapeutics

Market Overview
Autoimmune Disease Therapeutics Market to Gain from Increased Acceptance of Biologics by Physicians

The European autoimmune diseases therapeutics market is set to witness sustained growth in the coming years. Autoimmune diseases are caused by body’s immune responses directed on its own tissues. The immune system is designed to attack the infections caused by foreign bacteria and viruses. However, in an autoimmune disease, the immune cells in the body recognise the body’s own tissues as ‘foreign’ and the antibodies released by the immune cells act on various tissues in the body, leading to various disease conditions. There are over 70 autoimmune diseases including rheumatoid arthritis (RA), multiple sclerosis (MS) and psoriasis. It has been estimated that the prevalence rate of multiple sclerosis in Europe is 83 out of 100,000. Moreover, it is more common among women than men. In addition to this, two million people in Europe are affected by RA, which is one of the most common forms of autoimmune diseases, affecting 21 million people worldwide. However, the societal burden of autoimmune diseases is difficult to estimate as most of these diseases are debilitating, while some are less serious.

'The growing patient population and the need for better treatment options are the major driving forces in the autoimmune diseases therapeutics market in Europe,' notes the analyst of this research service. 'The increased uptake of biologics by physicians is also likely to have a significant impact on the sales of autoimmune disease therapeutics.' In addition, aggressive educational campaigns undertaken by pharmaceutical companies to promote new biologics are igniting interest among physicians and are expected to contribute to an increase in market revenues.

Awareness Programmes Crucial for Market Growth

Currently, the huge gap that exists between early diagnosis and the initiation of therapy is a critical factor restraining market growth. 'The complex nature of autoimmune diseases hinders the development of drugs that can cure these diseases,' explains the analyst. 'This scenario is worsened by low awareness of autoimmune diseases among patients, as well as physicians.' Thus, immense scope exists for improvement in translating the current knowledge of the autoimmune diseases to produce efficient therapeutics that can address the symptoms, as well as cure the disease.' Accordingly, researchers are striving to develop better therapeutics to reduce the burden of autoimmune diseases.

Meanwhile, various continuous medical education programmes will need to be conducted to inform the community about the implications of autoimmune diseases. These initiatives will promote the treatment of those affected with rheumatoid arthritis or multiple sclerosis and some form of drug for such autoimmune diseases can be administered to them.


Customers who bought this item also bought

Autoimmune Treatment (2009 - 2014)

Autoimmune Disease Therapeutics - Global Strategic Business Report

Autoimmune Disease Series: Systemic Sclerosis--Novel Treatment Approaches on the Horizon

Autoimmune Disease Therapeutics

European Autoimmune Disease Diagnostics Market

Autoimmune Market Outlook to 2012

Autoimmune Disease Series: Will Biologics Emerge as New Treatments for Reactive Arthritis?

Autoimmune And Inflammation Rheumatoid Arthritis

U.S. Autoimmune Disorders Markets for Biologics

Autoimmune Market Forecast to 2014

Commercial Insight: Autoimmune Overview - Market continues to prosper

The Autoimmune Outlook to 2013: Competitive Landscape, Pipeline Analysis and Growth Opportunities



Top of page


   All rights reserved. © Copyright 2009 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds